chrisvoncsefalvay/vaers-outcomes huggingface dataset:
4hr p/vax pt presented to ER w/nausea, vomiting, weakness, chills, t100.5;pt treated w/IV fluids, compazine & APAP;
Patent states he developed body aches, and low grade temp. a few hours after vaccination. Stated symptoms lasted 3 days, went away and returned 06/22/2007.Patient declined to come in for check today. States may come in tommorrow.
chest  painon the right side; pain from neck to shoulder; difficultly moving his arm; body pain in his side; felt weird; shoulder pain; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (chest  painon the right side), NECK PAIN (pain from neck to shoulder), LIMB DISCOMFORT (difficultly moving his arm), PAIN (body pain in his side) and FEELING ABNORMAL (felt weird) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 29-Jul-2021 at 2:40 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jul-2021, the patient experienced CHEST PAIN (chest  painon the right side), NECK PAIN (pain from neck to shoulder), LIMB DISCOMFORT (difficultly moving his arm), PAIN (body pain in his side), FEELING ABNORMAL (felt weird) and ARTHRALGIA (shoulder pain). At the time of the report, CHEST PAIN (chest  painon the right side), NECK PAIN (pain from neck to shoulder), LIMB DISCOMFORT (difficultly moving his arm), PAIN (body pain in his side), FEELING ABNORMAL (felt weird) and ARTHRALGIA (shoulder pain) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided by the reporter.   Treatment information was not provided.
Severe explosive diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Severe explosive diarrhea) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 028L20A) for COVID-19 vaccination.     Concurrent medical conditions included Rheumatoid arthritis. Concomitant products included TOFACITINIB CITRATE (XELJANZ XR) for Rheumatoid arthritis.   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced DIARRHOEA (Severe explosive diarrhea). At the time of the report, DIARRHOEA (Severe explosive diarrhea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment of events was reported.  The reporter mentioned the patient withheld her doses of Xeljanz for 5 days prior to her second dose of Moderna vaccine and did not experience the event of explosive diarrhea again.   Most recent FOLLOW-UP information incorporated above includes: On 21-May-2021: Follow-up received: Medical history, vaccine information, concomitant medication information and event information were updated.
I found out that I have the following problems after being vaccinated. I never felt like this before in my life??. The arthritis and all the other problems are hard to deal with .  I have never had these problems before the shots and my family does not have history of these conditions.   1. Osteoarthritis in the spine ??. 2. Facet Joint Disease  3. Bone Spurs 4. Minimal Convex Left Curvature of Lumber Spine with apex at L3. 5. Mild Multilevel Disc Desiccation 6.Facet Arthropathy 7. Undiagnosed Soft/hard Masses ( doctors can not tell what they are. There are multiple soft masses that are movable that do not show up on the MRI.) 8. Chronic pain that makes it hard to move around and sleep .
hospitalized with right leg DVT and bilateral massive pulmonary embolism 21Feb2021; hospitalized with right leg DVT and bilateral massive pulmonary embolism 21Feb2021; Presumed my extreme fatigue and shortness of breath following day was common side effect.; shortness of breath following day was common side effect.; This is a spontaneous report from a contactable nurse. A 40-years-old female patient received first dose of BNT162B2 (PFIZER COVID-19 VACCINE) via an unspecified route of administration in right arm on 15Feb2021 17:45 (Batch/Lot Number: EW6201) as a single dose for covid-19 immunization. Medical history included hypothyroidism, asthma and obesity. Concomitant medications included ethinylestradiol, norgestimate (TRI LO MARZIA), levo-thyroxine sodium (SYNTHROID), montelukast sodium (SINGULAIR) and levocetirizine dihydrochloride (XYZAL); all taken for an unspecified indication from an unknown date (medications in two weeks). No other vaccine took in four weeks. No Known allergies. The patient was fully vaccinated with 2 doses, but the details completed with first vaccine information versus most recent due to that when event happened. First Vaccine received 15Feb2021; Presumed her extreme fatigue and shortness of breath following day was common side effect; symptoms worsened; hospitalized with right leg DVT and bilateral massive pulmonary embolism on 21Feb2021. The above adverse events started on 16Feb2021. The adverse resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event. Number of days of hospitalization was seven. The treatment was given with TPA, IV Heparin, Thrombectomy, Surgery, Xarelto. No covid prior vaccination. The patient had been covid tested post vaccination with nasal swab type rapid test on 07Aug2021 resulted in positive. The outcome of the events was recovering.  Information about lot/batch number has been requested.; Sender's Comments: Based on the information available and close temporal association, a possible contributory role of the suspect BNT162B2 cannot be excluded for the reported events . The case will be reassessed once new information is available   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Per parent's report at approximately 9:15am on 8/14/19 child fainted while in their car leaving the pediatrician's office.  Child did not hit her head.  Child c/o headache and abdominal pain.  Parent was offered an appointment to evaluate child, but parent declined.  Update from parent was received by pediatrician's office on 8/14/19 at 3:35pm.  Per parent, child still c/o a slight headache.
CLOT IN MY THUMB; CLOT IN THE BRAIN; 4 STROKES; STRICKEN WITH COVID-19 RIGHT AROUND THE TIME I WAS VACCINATED; SUSPECTED CLINICAL VACCINATION FAILURE; This spontaneous report received from a patient concerned a 52 year old male of unspecified race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number: 206A21A) dose, start therapy date were not reported, frequency 1 total for prophylactic vaccination. Dose number series was 1. No concomitant medications were reported.  On an unknown date, the patient was stricken with COVID 19 at the time of vaccination (suspected clinical vaccination failure). Less than a week  after receiving the vaccine the patient developed a clot in thumb that broke off and went to the brain. The patient suffered four strokes as a result. Ultimately, the patient was hospitalized for 2.5 months. During this time the patient was on a ventilator and required cardiopulmonary resuscitation (CPR) numerous times. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the clot in my thumb, clot in the brain, 4 strokes, stricken with covid-19 right around the time I was vaccinated and suspected clinical vaccination failure was not reported. This report was serious (Hospitalization Caused / Prolonged, and Life Threatening). This report was associated with a regulatory authority. The suspected regulatory authority has been confirmed to be voided (patient confirmed during outreach that he got covid either 1 week before or 1 week after he was vaccinated, but doesn't remember. since infection occurred either before vaccination and less than 28 days after vaccination, this complaint does not qualify as an LOE and does meet the definition of a PQC. complaint is being sent for void approval). based on the PQC evaluation/investigation performed.; Sender's Comments: V0: 20211234782 -Covid-19 vaccine ad26.cov2.s- Clot in my thumb, clot in the brain, 4 strokes, stricken with covid-19 right around the time I was vaccinated. This event(s) is considered unassessable. The event(s) has an compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). V0: 20211234782 -Covid-19 vaccine ad26.cov2.s- Suspected clinical vaccination failure. This event(s) is considered not related. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS.
COVID-19 treatment; COVID-19 treatment; This is a spontaneous report received from a non-contactable reporter(s) (Nurse). The reporter is the patient.  A 58-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "HTN" (unspecified if ongoing), notes: other medical history: HTN. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19 treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19. Brand: Paxlovid. Treatment start date: 03Jun2022. Treatment stop date: 07Jun2022.  No Follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product bnt162b2 to the reported drug ineffective / COVID-19 cannot be ruled out
ear pain on the side I got the shot; neuralgia on the inside of my head; This is a spontaneous report from a contactable consumer (patient) or other non hcp. A 70-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 via an unspecified route of administration on 19Feb2021 (Batch/Lot number was not reported, age at the time of vaccination: 70-year-old) as DOSE 1, SINGLE for covid-19 immunisation.The patient medical history and concomitant medications were not reported.The patient experienced ear pain on the side i got the shot, neuralgia on the inside of my head on 19Feb2021.The patient received her first Pfizer Covid-19 Vaccination last Friday, 19FEB2021. On Friday night (19Feb2021) she began experiencing "ear pain on the side I got the shot, in my scull, like you would brush your head, like neuralgia on the inside of my head." Patient stated the pain is still there and asked was this common. And also asked if there is any information regarding MRI with contrast? Would an MRI with contrast interfere with the efficacy of the vaccine? Should she wait till after she get her second vaccine to get the MRI. The outcome of events was reported as not recovered.  No follow-up attempts are possible; information about lot/batch number cannot been obtained
approx 1mo p/vax pt devel swelling of both hands;pt had a h/a for 2wk prior to vax;the h/a persisted for 4wk post vax;pt underwent testing for lyme disease, CHF, & liver function;no abnormalities were found;
Initially there were no issues.  19 days later I had a LAD heart attack with only 1 artery occluded.  The two arteries were clear.
dizzy, lightheaded, flushing, nausea, sweating, anxious.
Pt. presents to EC on 05/19/2021 w/ "Pt with pmh of esophageal varicies, prior GIB (3 years ago varices and upper GIB) awke this am 0100 vomiting coffee ground emesis. +aspirin use for 1 mo. ETOH abuse. Denies cp, LE edema, sob, abdominal pain or any other concerns. Denies fever", also w/ nausea & vomiting.
Hx of dementia and recent pneumonia; diagnosed positive for COVID 1 wk ago in nursing facility; has been in isolation in the facility; presents to ED with cough; on 4 L O2 via NC, sats in the 90s; increased confusion during the course of hospitalization; condition worsened; encephalopathy; antibiotics and O2 supplementation given; mental status never recovered; comfort care measures in place; pt died in the hosp
multiple outbreaks of herpes zoster; PHN; vision problems; balance problems; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions, previous drug reactions, allergies and concomitant medications. On an unknown date, the patient was inoculated with zoster vaccine live (ZOSTAVAX) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster) (Strength, dose, frequency, route of administration, lot number and expiration date were not reported). On unknown dates, after receiving zoster vaccine live (ZOSTAVAX), the patient sufferedmultiple outbreaks of herpes zoster, postherpetic neuralgia, vision problems and balance problems. As result of these symptoms, the patient was seen and treated by medical providers and was still under their care. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms had resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX). The patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of patient's condition; sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX) wrongful conduct, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury; and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events was not recovered. The lawyer considered the events to be related to zoster vaccine live (ZOSTAVAX).
Symptoms: chills, low body temperature (especially at night, last night's measure: 96.2 F), muscle pain (particularly around kidneys' area),  joint pain, and headaches.   Treatment: after 3 days of persistent symptoms, I talked to a doctor who recommended taking ibuprofen. I took ibuprofen for 3-4 days which mitigated the symptoms. Symptoms returned after a few days and persisted until now (17 days after vaccination)
This case was reported by a other health professional via call center representative and described the occurrence of shingles in a adult patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, unknown after receiving SHINGRIX, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown. It was unknown if the reporter considered the shingles to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as an adult per the vaccine indication. After initial dose of SHINGRIX, the patient developed a Shingles outbreak.
In early January 2023 I was brushing my hair and noticed I had a lump on my neck. My annual physical was coming up so I waited to have her look at it then. She ordered an ultra for February 15, 2023. The ultrasound came back showing an enlarged lymph node. We consulted on this report, and I have had another full physical of all lymph node areas, along with the questions that come with having an enlarged lymph node. I will be having a CT scan scheduled soon, we are awaiting for when they have an opening.
Information has been received from a female consumer who on an unspecified date was vaccinated with GARDASIL (Lot #, and route not reported).  The consumer reported that on an unspecified date she developed a seizure disorder.  At the time of the report, the outcome of the patient was not reported.  It was unknown if the patient sought medical attention.  The reporter felt that seizure disorder was related to therapy with GARDASIL.  Upon internal review, seizure disorder was considered to be another important medical event.  No further information is available.
patient given an expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient given an expired vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (patient given an expired vaccine). On 06-May-2021, EXPIRED PRODUCT ADMINISTERED (patient given an expired vaccine) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.   Treatment information was not provided.  Pharmacist stated that she saw a mostly full vial in the refrigerator from the previous day that had been punctured and exposed for 12 hours and was no longer valid.   This case was linked to US-MODERNATX, INC.-MOD-2021-114456, US-MODERNATX, INC.-MOD-2021-114420, US-MODERNATX, INC.-MOD-2021-114626 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 10-May-2021: Non-significant follow-up On 10-May-2021: non significant follow up; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-114456: US-MODERNATX, INC.-MOD-2021-114420: US-MODERNATX, INC.-MOD-2021-114626:
Initial report received on 18/Aug/2006 from a nurse.  A 52-year-old female patient with no current illnesses had received a dose of Tripedia, lot number U1751CA, in the left deltoid, on 17/Aug/2006 at 13:00 pm.  The route of administration was not reported.  The manufacturer of the Tripedia vaccine does not recommend this vaccine in patient's 54 years of age.  The next day, the patient developed a fever of 102.8 degrees Fahrenheit, chills, burning sensation in her knees and hips, and generalized joint and muscle aches.  She also had injection site soreness.  Treatment was not reported.  The recovery status of the patient was reported as not recovered.   The reporter for this case is the as for case 2006-02201.
Patient reported tingling in fingers of right hand. Started about 1 minute after vaccine administration. Patient states he has a history of a pinched nerve in his neck that affects is right hand.  Patient's wife states patient turned awkwardly when getting vaccine and this may have bothered his pinched nerve.   Consulted Dr and after observing patient it was recommended that he follow-up with his Primary care doctor that follows his pinched nerve.
Redness, swelling, pain, itching, burning and heat at injection site. As of 30 hours post injection the swelling has reached 13cm across surrounding the injection site.
received a third dose of Menveo; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 17-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA928A, expiry date 31-MAR-2025) for prophylaxis.   On an unknown date, the patient received the 3rd dose of Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: received a third dose of Menveo).The outcome of the extra dose administered was unknown.   Additional Information: GSK Receipt Date: 22-AUG-2023 The reporter reported that a patient that received a third dose of Menveo, which led to extra dose administered. The reporter did not consent to follow-up.
Received the first COVID shot on 1-17-21 and began to feel pain in the back of my neck on the right side in the afternoon of 1-19-21. On 1-20-21 I lost part of my taste and neck started to cause headaches. On 1-21-21 symptoms continued to get worse. On 1-22-21 I began to lose control of the right side of my face. Face began to droop and eye was unable to close. I went to the ER on the evening of 1-22-21 and was diagnosed with Bell's Palsy.
Minor soreness and headache day of and day after, then fine until one week later, when I noticed it itching quite a lot. The shoulder is hardened, slightly reddened and warm - still today as it was Sunday, May 2nd.
Via phone, pt stated about 45 min after vaccination to experienced nasal congestion, plugged ears, dizziness, increased confusion shortly after all these symptoms. Pt declined seeing MD/ER at this time.
started high pitched screaming episode @ 6PM lasted 2 hrs; inconsoleable; no fever, leg sore used APAP;
Information has been received from a registered nurse concerning a 4 week old patient who on 16-JUL-2008 was vaccinated with ROTATEQ vaccine live (human-bovine). There were no adverse events reported. At the time of the report, the patient's status was unknown. There was no product quality complaint involved. Additional information has been requested.
pt recvd vax & 24 hrs p/each dose exp lt arm rash; sx resolved p/each dose; pt recvd dose of 15FEB94;
This spontaneous case, initially received from the other health professional (nurse) on 07-Nov-2018, concerns a 42-year-old, adult male patient. On an unspecified date, the vaccines were stored in the refrigerator and eventually a temperature drop was noted for a moment up to plus 0.3 Celsius for less than 115 minutes, which was considered as first temperature excursion. It was reported that the vaccines were moved immediately. On 26-Oct-2018, the patient was administered FLUCELVAX QIVc (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: 252227 and expiry date: 31-May-2019) which underwent temperature excursion. The patient experienced no adverse event after the vaccination. This case (201805345) was cross-linked to the source case 201805327 reported by the same reporter. The reporter assessed this case as non-serious. Follow-up received from the nurse on 28-Nov-2018: Age of the patient was added in the patient tab. Route of administration and anatomical location was added in the product tab. It was reported that the patient had not experienced any adverse event after the vaccination. Narrative and case comment were amended accordingly.